MedTrace Logo

Carnosine and Cognitive Training in Schizophrenia

NCT02686697 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-08-23

No results posted yet for this study

Summary

This is a double-blind placebo-controlled trial to evaluate the effects of the combination of a cognition enhancing drug, i.e carnosine, with cognitive training in patients with schizophrenia. All participants will receive the same cognitive training sessions and will be randomised to either carnosine or placebo for the duration of the combined treatment period (2 weeks). Before combined training and carnosine/placebo, there is a two-week carnosine/placebo only phase to examine the effects of carnosine alone on functioning without training.

Conditions

Interventions

DRUG

L-Carnosine

DRUG

Placebo

BEHAVIORAL

Cognitive Training

Cognitive Training for 2 weeks

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Abraham Reichenberg

    lead OTHER

Principal Investigators

  • Avi Reichenberg, PhD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-01
Primary Completion
2022-07-19
Completion
2022-07-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02686697 on ClinicalTrials.gov